Interestingly and in line with our mouse data is a recent phase IIa, randomized, double-blind, placebo-controlled trial of an IL-12/IL-23 inhibitor in patients with rheumatoid arthritis that showed no clinical improvement in RA [11]. Here, IL23A is linked to rheumatoid arthritis.